European Journal of Biotechnology and Bioscience

Authors
Harit Kasana

Abstract
Infliximab is a chimeric IgG1κ monoclonal antibody (composed of human constant and murinernvariable regions) specific for human tumor necrosis factor-alpha (TNFα). Infliximab is produced by arnrecombinant cell line cultured by continuous perfusion and is purified by a series of steps that includesrnmeasures to inactivate and remove viruses. The annual global sale of Infliximab was $8 billion in 2013,rnaccording to industry data. This article describes the overview of infliximab including mechanism ofrnaction, indications and development genetics.